RBM15 and Alzheimer disease: In line with previous reports, we observed increased expression of m6A writers (e.g., METTL3, RBM15/15B, WTAP), reduction in m6A erasers (e.g., FTO) and dysregulation of several m6A readers (e.g., HNRNPA2B1, RBM27, PCIF1, YTHDF2, YTHDC2, HNRNPC/D, etc.)in the hippocampus of 5xFAD and/or APP-NLGF mice, compared to age matched controls; with MS1262 treatment reversing AD-dysregulated expression of several m6A regulators (Fig. S4B).